Compare AbbVie Inc (ABBV) vs Five9 Inc (FIVN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Five9 Inc — how do they compare? AbbVie Inc trades at $250.2 (market cap $439.59B), while Five9 Inc trades at $32.62 (market cap $2.33B). The key difference: AbbVie Inc is far larger — about 188.7× Five9 Inc's market cap, and AbbVie Inc pays a 2.78% dividend while Five9 Inc pays none. Which is the better fit depends on your goals.
| ABBV | FIVN | |
|---|---|---|
Market Cap | $439.59B | $2.33B |
Sector | Health | Technology |
52-Week High | $263.58 | $34.48 |
52-Week Low | $197.38 | $13.61 |
Enterprise Value | $503.84B | $2.48B |
Dividend Yield | 2.78% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $250.13, up 0.08% on the day, with a bullish technical signal and strong analyst support. Recent earnings beats, including Q2 2026 EPS of $3.65 versus $3.61 expected, highlight operational strength. Revenue growth is robust, projected to rise to $64.4B in 2026, driven by immunology drugs Skyrizi and Rinvoq offsetting Humira declines. The stock nears resistance at $252, with a consensus price target of $278.69 suggesting 11% upside.
Outlook is positive due to pipeline advancements, such as Phase 2 ovarian cancer data (PRNewsWire, April 12, 2026), and dividend reliability. Risks include patent expirations in the 2030s and high debt levels. With 71% analyst buy ratings and institutional accumulation, ABBV offers growth and income, but investors must monitor competitive and regulatory pressures.
Five9 (FIVN) trades at $31.14, down 9.69% today but remains near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and has consistently beaten earnings estimates in recent quarters. Revenue growth accelerated to 10% in Q2 2026, reaching $312.4 million, while the company maintains a solid gross margin of 54.91%. Recent management appointments and AI-driven subscription growth provide positive catalysts.
The outlook remains positive with 61% analyst buy ratings and a $32.67 consensus target offering 5% upside. However, elevated valuation multiples (P/E 47.99) and ongoing fiduciary investigations pose risks. The stock's trajectory depends on continued execution of AI revenue growth and margin expansion targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Five9 Inc
Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →
